HC Wainwright Issues Positive Forecast for WVE Earnings

WAVE Life Sciences Ltd. (NASDAQ:WVE) – Analysts at HC Wainwright lifted their Q3 2026 EPS estimates for shares of WAVE Life Sciences in a report released on Friday, July 31st. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.29) for the quarter, up from their prior estimate of ($0.30). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for WAVE Life Sciences’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for WAVE Life Sciences’ Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.05) EPS, FY2027 earnings at ($0.88) EPS, FY2028 earnings at ($0.79) EPS, FY2029 earnings at ($0.68) EPS and FY2030 earnings at ($0.47) EPS.

Other analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of WAVE Life Sciences in a research report on Friday, July 17th. Wells Fargo & Company raised their target price on shares of WAVE Life Sciences from $13.00 to $14.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. UBS Group set a $13.00 target price on shares of WAVE Life Sciences in a report on Monday. Truist Financial began coverage on shares of WAVE Life Sciences in a research report on Wednesday, April 29th. They issued a “buy” rating and a $15.00 price target for the company. Finally, Canaccord Genuity Group decreased their price target on shares of WAVE Life Sciences from $52.00 to $43.00 and set a “buy” rating for the company in a research note on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.76.

WAVE Life Sciences Stock Up 4.2%

Shares of WAVE Life Sciences stock opened at $5.74 on Tuesday. The firm has a market capitalization of $1.13 billion, a P/E ratio of -5.27 and a beta of -1.26. WAVE Life Sciences has a 52 week low of $5.02 and a 52 week high of $21.73. The firm’s 50 day moving average is $5.96 and its two-hundred day moving average is $8.88.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.04). The business had revenue of $2.27 million for the quarter, compared to analyst estimates of $7.45 million. WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%.

Institutional Trading of WAVE Life Sciences

A number of institutional investors have recently bought and sold shares of the company. Pictet Asset Management Holding SA grew its stake in WAVE Life Sciences by 5,024.6% in the 4th quarter. Pictet Asset Management Holding SA now owns 805,901 shares of the company’s stock worth $13,830,000 after acquiring an additional 790,175 shares during the period. F m Investments LLC increased its position in WAVE Life Sciences by 24.5% during the fourth quarter. F m Investments LLC now owns 395,894 shares of the company’s stock worth $6,730,000 after purchasing an additional 77,807 shares during the last quarter. Prescott Group Capital Management L.L.C. purchased a new stake in WAVE Life Sciences during the fourth quarter valued at about $1,530,000. Elmind Capital LP purchased a new stake in shares of WAVE Life Sciences during the 4th quarter worth about $7,613,000. Finally, Capstone Capital Management Ltd purchased a new stake in WAVE Life Sciences during the first quarter worth approximately $1,044,000. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.